Recombinant human placental growth factor-2 in post-infarction left ventricular dysfunction: a randomized,...

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Translational Science

Background:

• Placental growth factor (PlGF)-2 shows potential for promoting blood vessel growth.
• Its efficacy in treating post-myocardial infarction (MI) left ventricular (LV) dysfunction is not well-established in clinically relevant models.

Purpose of the Study:

• To investigate the safety and efficacy of recombinant human PlGF-2 (rhPlGF-2) in a porcine model of post-MI LV dysfunction.
• To assess rhPlGF-2's impact on neovascularization and cardiac function.

Main Methods:

• Myocardial infarction induced in pigs via balloon occlusion, followed by reperfusion.
• Pigs with LV dysfunction randomized to receive rhPlGF-2 or placebo (PBS) via continuous intravenous infusion for two weeks.
• Treatment effects evaluated at eight weeks using cardiac MRI, immunohistochemistry, and molecular analysis.

Main Results:

• rhPlGF-2 administration was safe, showing dose-dependent plasma concentrations without systemic toxicity.
• No significant differences observed in infarct size, vascular density, LV function, or myocardial blood flow between groups.
• Significant downregulation of the PlGF-2 receptor (pVEGFR-1) noted in dysfunctional myocardium.

Conclusions:

• Chronic rhPlGF-2 infusion is safe but failed to induce therapeutic neovascularization or improve cardiac function post-MI in pigs.
• The study highlights the need for robust large animal model studies before human clinical trials.